Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 106INDUSTRY 16NETWORK 5NIH 3OTHER_GOV 2FED 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Neoplasms 1Leukemia 1

Interventions

fludarabine 5Cyclophosphamide 5Azacitidine 4Cytarabine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2bisantrene 2Metformin 2Etoposide 2Dasatinib 2Clofarabine 2Busulfan 2vosaroxin 1treosulfan 1peginterferon alfa-2a 1nilotinib 1liposomal amphotericin B 1fludarabine phosphate 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1cc-486 1aldesleukin 1Zinc Sulfate 1Zinc 1Vitamin D 1Urination 1Tranexamic Acid 1Thiotepa 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Clofarabine × Other hematologic neoplasm × Clear all
NCT05477589 2024-12-19

SCRIPT-AML

Vastra Gotaland Region

Phase 3 Recruiting
170 enrolled
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute

NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown
29 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡